Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Share-based Compensation (2016 - 2025)

Dexcom (DXCM) has disclosed Share-based Compensation for 16 consecutive years, with $35.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 19.17% to $35.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.6 million through Dec 2025, down 6.34% year-over-year, with the annual reading at $159.6 million for FY2025, 6.34% down from the prior year.
  • Share-based Compensation for Q4 2025 was $35.0 million at Dexcom, down from $45.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $45.3 million in Q2 2025, with the low at $26.3 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $36.0 million, with a median of $35.1 million recorded in 2023.
  • The sharpest move saw Share-based Compensation decreased 22.87% in 2021, then grew 29.28% in 2022.
  • Over 5 years, Share-based Compensation stood at $26.3 million in 2021, then increased by 29.28% to $34.0 million in 2022, then grew by 8.53% to $36.9 million in 2023, then rose by 17.34% to $43.3 million in 2024, then decreased by 19.17% to $35.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $35.0 million, $45.1 million, and $45.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.